Efalizumab in the treatment of psoriasis.
The humanized antibody efalizumab is currently the only T-cell directed biologic approved for the treatment of moderate-to-severe psoriasis by both American and European authorities. Binding to and blocking the function of the adhesion molecule leukocyte function associated antigen 1 (LFA-1), it is believed to interfere with T-cell activation in the lymph node, migration through the circulation into the skin, and re-activation in-loco, all of these representing central steps in the pathogenesis of psoriasis. A comprehensive clinical development program provided large and consistent evidence that efalizumab induces a major clinical benefit in psoriasis. Efalizumab rapidly and substantially improves psoriatic skin symptoms and leads to profound gain in quality of life. It allows safe and effective long-term control of psoriasis. Therefore, evidence-based treatment guidelines recommend its use in moderate to severe plaque-type psoriasis.
Boehncke
Wolf-Henning
WH
Department of Dermatology, Johann Wolfgang Goethe-University, Frankfurt am Main, Germany.
J Am Acad Dermatol. 2002 Jan;46(1):1-23; quiz 23-6
11756941
JAMA. 2003 Dec 17;290(23):3073-80
14679270
Arch Dermatol. 2005 Jan;141(1):82-4
15655149
J Rheumatol. 2006 Jul;33(7):1447-51
16724367
J Invest Dermatol. 1978 Nov;71(5):340-3
309493
J Am Acad Dermatol. 2006 Apr;54(4 Suppl 1):S182-8
16488340
Br J Dermatol. 2004 Aug;151 Suppl 69:3-17
15265063
Arch Dermatol. 2005 Jan;141(1):31-8
15655139
J Rheumatol. 2006 Jul;33(7):1442-6
16724368
Br J Dermatol. 2005 Sep;153(3):486-97
16120132
J Am Acad Dermatol. 1999 Oct;41(4):581-3
10495380
J Clin Pharmacol. 2005 Mar;45(3):286-98
15703364
Am J Pathol. 1999 Jul;155(1):145-58
10393847
Nat Immunol. 2004 Apr;5(4):363-72
15052266
N Engl J Med. 2003 Nov 20;349(21):2004-13
14627785
J Am Acad Dermatol. 2001 Nov;45(5):665-74
11606914
BMJ. 1990 Apr 7;300(6729):908
2337714
J Eur Acad Dermatol Venereol. 2006 Sep;20(8):988-98
16922950
J Am Acad Dermatol. 2006 Apr;54(4 Suppl 1):S154-63
16488337
N Engl J Med. 2005 May 5;352(18):1899-912
15872205
J Am Acad Dermatol. 2005 Mar;52(3 Pt 1):425-33
15761420
J Am Acad Dermatol. 2000 Mar;42(3):428-35
10688712
J Am Acad Dermatol. 1999 Sep;41(3 Pt 1):401-7
10459113
J Immunol. 1985 May;134(5):3272-80
2580022
Arch Dermatol. 1990 Nov;126(11):1523
2241215
J Dtsch Dermatol Ges. 2006 Nov;4 Suppl 2:S1-126
17187649
Arch Dermatol. 2002 May;138(5):591-600
12020219
J Investig Dermatol Symp Proc. 2004 Mar;9(2):136-9
15083780
J Immunol. 1996 Dec 1;157(11):4986-95
8943405